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ABSTRACT: Stromal cells from the prostate were recently shown to inhibit clonal 
growth of the prostatic carcinoma cell lines PC-3 (hormone-independent) and LNCaP (hor- 
mone-sensitive) in coculture. Our study revealed that stromal cell-conditioned medium 
strongly inhibited proliferation of PC-3 and LNCaP cells when grown in monolayer culture. 
Antiproliferative activity was found to be reversible, and was produced specifically by pro- 
static stromal cells and not by stromal cells derived from skin, foreskin, uterus, kidney, and 
Wilms’ tumor. Inhibition was not species-specific, since the cell lines AT-2.1 and MATLyLu, 
derived from the Dunning rat prostate tumor, were also sensitive. No inhibition, however, 
occurred on breast and renal carcinoma cell lines, suggesting a prostate-specific action. The 
putative inhibiting factor(s) could be concentrated and partially purified by ammonium 
sulfate precipitation. The possible role in stromal control of epithelial cell proliferation is 
discussed. 0 1995 Wiley-Liss, Inc. 
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INTRODUCTION 
Since the observation was made that the epithe- 
lium loses its growth capacity when separated from 
the stroma [l], it has become increasingly clear that 
stromal-epithelial interactions play an important role 
in the local control of prostatic growth. The impor- 
tance of embryonic mesenchyme in prostatic ductal 
morphogenesis, and epithelial cell growth and differ- 
entiation, has been demonstrated by a unique series 
of tissue-recombinant experiments [2]. Several obser- 
vations have indicated that these interactions might 
have retained their integral role in the adult prostate 
as well [2,3]. It is for this reason that the development 
of cancer and other disease states is thought to in- 
volve a loss of coordination in such interactions. 
McNeal [4] has already suggested the reversion of 
prostatic stroma to an “embryological state,” induc- 
ing inappropriate epithelial proliferation in benign 
prostatic hyperylasia (BPH). 
Upon maturation, accessory sexual organs reach a 
typical size and weight which is characteristic for 
those particular organs [2]. Likewise, administration 
of testosterone to androgen-deprived rats restores the 
size of the prostate to its normal precastration level 
without inducing overgrowth, even after prolonged 
administration [2]. At that stage, epithelial cell pro- 
liferation is low and in balance with cell death [5]. 
Experiments performed by Cunha and Chung [6] 
showed that epithelial cell growth and, therefore, ab- 
solute prostatic size was regulated by the amount of 
mesenchymal (stromal) tissue present. During em- 
bryological development, androgen receptors are 
present only in the mesenchyme, indicating that all 
androgen-induced events are mediated via the 
stroma [2,3]. Furthermore, it was also shown that in 
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the adult rat prostate, the proliferative response to 
androgens was mediated through the stroma [7] .  At 
this point it is tempting to speculate upon a similar 
role of the stroma in castration-induced involution of 
the gland. Androgen-induced stromally derived in- 
hibitors of epithelial cell growth would participate in 
keeping the delicate balance between cell prolifera- 
tion and programmed cell death. The observation 
that rat and human prostatic epithelial cells grown in 
vitro are able to proliferate in serum-free medium 
without the presence of androgens [8-111, while an- 
drogen ablation in vivo induces a marked regression 
of the glandular epithelium [5], indicates a major role 
for the stroma in a negative control of epithelial cell 
proliferation. Several investigators have been search- 
ing for the molecular basis of this homeostatic con- 
straint mechanism that curtails further increase in cell 
number once the gland has reached its predeter- 
mined size. Biochemical analyses have shown the 
presence of (polypeptide) growth inhibitors in the 
prostate but, since these determinations were per- 
formed on whole-tissue homogenates, it is still not 
clear whether these are produced by the stroma or 
the epithelium [ 12,131. 
The present study further explores the hypothesis 
of a negative control by the stroma. Using a two-layer 
soft agar assay, we previously observed an inhibition 
of the clonal growth of human prostate tumor epithe- 
lial cell lines PC-3 (hormone-independent) and LN- 
CaP (hormone-sensitive) by cocultured prostatic stro- 
ma1 cells [14]. To elucidate this interaction further, we 
established a number of stromal cell cultures from 
human prostatic carcinomas as well as benign pros- 
tatic hyperplasia nodules, and investigated the influ- 
ence of conditioned medium (CM) of these cultures 
on the anchorage-dependent growth (monolayer cul- 
tures) of different epithelial cell lines from human 
and murine origin. Likewise, several nonprostatic 
stromal cell cultures were initiated, and their CM 
tested. The results demonstrated that only prostatic 
stromal cells accumulate inhibitory activity in the 
(conditioned) medium. Anchorage-dependent as 
well as anchorage-independent growth of prostatic 
carcinoma cell lines was inhibited in a dose-related 
fashion. The possible role of the stroma in a negative 
control of epithelial cell proliferation is discussed. 
MATERIALS AND METHODS 
Stromal Cell Cultures 
Histologically proven tissue specimens from be- 
nign prostatic hyperplasia (BPH) and prostatic carci- 
noma (PC), obtained by surgery, were cut into pieces 
(approximately 1 x 2 mm) and placed in 35 mm petri 
dishes (Nunc) containing 1.5 ml basal medium: 
Earle's Minimum Essential Medium (Gibco Europe, 
Breda, the Netherlands) supplemented with 10% Fe- 
tal Calf Serum (FCS) (Biological Industries, Beth Hae- 
mak, Israel), 2 mM glutamine, penicillin, and strep- 
tomycin (all from Gibco Europe). Cultures were 
maintained in a humidified incubator at 37°C in 5% 
CO,/air. Medium was replaced twice a week. The 
initial halo of epithelial cells grown from these ex- 
plant cultures became overgrown with fibroblast-like 
cells within several weeks. Subsequently, cells were 
detached by trypsinization (0.05% in 0.02 EDTA) 
(Gibco Europe) and split in a 1:3 ratio every 2-3 
weeks. In order to minimize the number of epithelial 
cells in our cultures (none were detected morpholog- 
ically), we only used prostatic stromal cells of passage 
numbers 4-9 in this study. Using the monoclonal an- 
tibody NCL5D3 (Organon, Oss, The Netherlands) re- 
acting with Keratins 8,18, and 19, we found the num- 
ber of positive cells in these cultures (BPH as well as 
PC) varying between 0-5%, indicating that nearly all 
cells were of nonepithelial origin. Stromal cell cul- 
tures from skin, foreskin, uterus, kidney, and Wilms' 
tumor specimen were established in the same way. 
Cell Lines 
The prostatic carcinoma cell line PC-3, obtained 
from Flow Laboratories (Irvine, Scotland) and main- 
tained in basal medium, was used between passage 
numbers 30-45. LNCaP-FGC cells (used at passage 
numbers 65-70), originally made available to us by 
Dr. J. Horoszewicz (Buffalo, NY), and the Dunning 
rat prostate tumor cell lines AT-2.1 and MATLyLu, 
kindly provided by Dr. J.A. Schalken (University of 
Nijmegen, The Netherlands), were all cultured in 
RPMI 1640 (Gibco Europe) supplemented with 10% 
FCS, glutamine, and antibiotics. The renal carcinoma 
cell line RC-21, established at our laboratory, was cul- 
tured in basal medium. The breast carcinoma cell line 
MCF-7 (pass. nr. 330), generously given by Dr. 
P.M.J.J. Berns (Daniel den Hoed Cancer Center, Rot- 
terdam, The Netherlands), was cultured in RPMI 
1640 (Gibco Europe) containing 10% FCS, 2 @ml 
insulin (Sigma, St. Louis, MO), glutamine, and anti- 
biotics. All cultures were shown to be free of myco- 
plasma contamination by staining with Bisbenzimide 
(Hoechst dye 33258) obtained from Sigma. 
Collection of Conditioned Medium (CM) 
Prostatic stromal cell conditioned medium ( ~ 0 . 2  
ml/cm2) was collected twice a week from confluent 
monolayers. After centrifugation (6,000 g; 20 min; 
4"C), CM was stored at -20°C until further use. 
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Growth Inhibition Assay 
Inhibition of anchorage-dependent cell growth 
was determined by means of a colorimetric assay 
based on the reduction of a tetrazolium salt, 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro- 
mide (MTT), to a colored formazan product (maxi- 
mum absorption at 560 nm) by mitochondria1 
enzymes present only in living, metabolically active 
cells [15]. Results of these MTT-tests performed on 
prostatic epithelial cell lines were shown to correlate 
well with those obtained with [3H]-thymidine incor- 
poration assays and with direct DNA measurements 
[15,11]. Cells were harvested by trypsinization, resus- 
pended in fresh culture medium, and plated in a vol- 
ume of 0.1 nil per well in 06-well microtiter plates 
(Costar). Inoculum: 2,000 PC-3 cells per well. The 
next day (day 0), 0.1 ml of sample was added, result- 
ing in a total volume of 0.2 ml, with a 50% dilution of 
the sample and a (basal) FCS concentration of 5%. At 
day 3, 30 pl of a 5 mg/ml solution of MTT (Sigma) in 
PBS was added to each well. After a 4-hr incubation 
at 37°C in 5% CO,/air, the medium was carefully 
drawn off and the purple dye was dissolved in 0.1 ml 
DMSO (Merck, Darmstadt, Germany) containing 
12.5% of a 0.1 M Sorensen buffer pH 10.5. Plates were 
placed on a plate shaker for 5 min, and the absor- 
bance at 560 nm was read using a Flow Titertek Mul- 
tiskan plate reader. Unless otherwise stated, eight 
replicate wells were used for each sample. Wells con- 
taining medium but no cells served as blanks. Results 
are expressed as percentage of maximal growth from 
day 0, obtained m fresh basal medium. To determine 
the number of cells at this point, one extra plate was 
read at day 0. 
Growth Curves 
Growth curves (Fig. 1) were determined in the 
presence of CM previously dialyzed (Spectrapor 
3-cutoff: 3500 Dalton; Spectrum Medical Ind., Los 
Angeles, CA)t against basal medium without serum. 
In order to avoid the formation of a confluent mono- 
layer, PC-3 cells were plated at a density of 1,000 
cells/well. MTT-tests were performed on separate 
plates at the days indicated. 
Production of Inhibitory Activity 
Stromal cells were plated in 24-well plates in 0.6 ml 
(= 0.3 ml/cm2) of basal medium and left to attach 
overnight. All wells were changed to fresh medium 
twice a week (days 1, 4, 8, and 11). At the days indi- 
cated, CM was harvested from two wells, pooled, 
and stored (at -20°C after centrifugation. Subse- 
quently, both monolayers were trypsinized and via- 
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Fig. I. A Inhibition of PC-3 cell growth by prostatic stromal cell 
CM. The left axis gives the absorbance at 560 nm as determined by 
the MTT test. Data labels on the right indicate the percentage of 
growth compared to  proliferation in basal medium. B: Reversibility 
of inhibition. At  day I or day 3, half of the cultures were changed 
to  fresh basal medium. Cultures initiated with CM, 0. Cultures 
initiated with basal medium, 0. Continuous lines, no medium 
change. Dashed lines, medium change at day I. Dotted lines, me- 
dium change at day 3. Inoculum, 1,000 celldwell. Error bar, SD. 
ble cells counted after addition of Trypan-blue. The 
average of these cell counts is given. After all samples 
were collected, inhibition of PC-3 cell growth by the 
respective CM was tested by means of the MTT-as- 
say. 
Concentration and Partial Purification of CM 
CM of different passages was pooled and fraction- 
ated by ammonium sulfate precipitation. This was 
performed through a stepwise increase in the level of 
saturation by adding solid ammonium sulfate (Sigma) 
to the medium at 0°C under continuous stirring [16]. 
At every 10% rise, the solution was centrifuged 
(10,000 g; 4°C; 20 min) and the pellet dissolved in PBS 
(Gibco). During this procedure, pH did not drop be- 
low 6.5. Samples from supernatant and pellet were 
extensively dialyzed (cutoff: 3.5 kD) at 4°C against 
PBS and MEM, respectively, and stored at -20°C af- 
ter sterilization through a 0.45 pm membrane (Schlei- 
cher & Schuell, 's-Hertogenbosch, The Netherlands). 
Osmolarity was checked to be 275-325 mOsm, using 
a Roebling osmometer (Vogel, Giessen, Germany). 
Protein Determination 
Protein concentrations were measured with the 
Bio-Rad Protein Assay Kit (Bio-Rad Labs, Veenen- 
daal, The Netherlands). A 1:l-mixture of the albumin 
and globulin solutions was used as a standard. 
126 Kooistra et al. 
Statistical Analysis 
All statistical comparisons were made using Stu- 
dent's paired t test analyses. Differences were con- 
sidered statistically significant if the two-tailed P 
value was smaller than 0.05. 
RESULTS 
Effect of Prostatic Stromal Cell CM on PC-3 Cells 
in Monolayer Cultures 
Anchorage-independent growth of human pros- 
tatic tumor epithelial cell line PC-3 was reported to be 
inversely correlated with the number of human pro- 
static stromal cells present in coculture experiments. 
Furthermore, it was shown that stromal cell CM in- 
hibited clonal growth of the hormone-independent 
PC-3 cells as well as the hormone-sensitive prostatic 
carcinoma cell line LNCaP [14]. As depicted in Figure 
lA, the anchorage-dependent culture (monolayer) of 
PC-3 cells was also inhibited by prostatic stromal cell 
CM. Growth inhibition, as determined by the MTT- 
test, of up to 45% was observed on the fourth day, as 
compared to growth in basal medium. At day 1 and 
day 2 the proliferation in CM was 53 and 55% of the 
controls, respectively. Growth in phosphate-buffered 
saline (PBS) was better than that found in dialyzed 
CM, indicating that the inhibition was not merely due 
to depletion of nutrients or mitogens from the me- 
dium, but was caused by diffusible growth inhibiting 
factor(s) present in the CM. Replacing CM with basal 
medium after 1 day of incubation resulted in a growth 
rate similar to that of controls (Fig. 1B). At that time, 
CM had decreased cell number to 50% of the control. 
However, no "catch-up" growth was observed. Sim- 
ilar observations were made when media were 
changed at day 3. These findings indicate that inhi- 
bition was reversible after removal of the inhibitory 
stimulus. 
Production of Inhibitory Activity by Prostatic 
Stromal Cells 
Figure 2, illustrating the "kinetics" of production, 
demonstrates the positive correlation between the 
number of stromal cells present and the level of in- 
hibition induced by their respective CM. About 
30,000-40,000 cells/cm2 were needed to induce a sta- 
tistically significant inhibition (more than 15%) of 
PC-3 cell growth. This level of inhibition was reached 
at day 2 and day 7, respectively, in cultures plated at 
high and low density. However, at higher cell densi- 
ties (250,000 cells/cm2), the correlation between cell 
number and inhibition no longer existed. Both cul- 
tures became density-arrested at the end of the sec- 
ond week. At this point, the graph shows that inhib- 
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Fig. 2. Production of inhibitory activity by prostatic stromal cells. 
Cells were plated in 24-well plates a t  two densities: a) 10,000 
cells/cm2 (open symbols), and b) 1,000 cells/cm2 (closed symbols). 
Medium was changed twice a week (A). A t  the days indicated, 
samples were taken and cell number counted (two wells). Left axis 
gives the number of stromal cells per cm2 represented by the 
dotted lines. Solid lines represent the inhibition of PC-3 cell 
growth by the respective CM as shown on the right axis. As a 
control, basal medium was incubated without cells, centrifugated, 
and stored as CM. Levels of significance were calculated using these 
control values. Inhibition > 15% showed to  be statistically signifi- 
cant (P50.05), while values >20% were highly significant 
(P50.005). 
itory activity still accumulated in time, illustrating its 
independence of proliferation as reported earlier [ 141. 
However, despite a clear difference in cell number, 
the CM caused equal levels of inhibition. Although 
the activity of the CM still appeared to be rising after 
four days, we considered this to be the maximal pe- 
riod for conditioning, for two reasons. First, after four 
days without medium refreshment, the stromal cells 
appeared less viable. Some cells detached from the 
substratum and were washed away with the me- 
dium, as is seen on day 8. Second, maximal activity, 
present in medium covering a confluent monolayer 
of stromal cells, usually did not exceed the 45% level, 
irrespective of whether it was conditioned for four 
days or longer. The fact that concentrating the CM 
enabled us to obtain higher levels of inhibition (see 
below), indicated that this critical level was not due to 
limitations in our test system. 
In order to find out if the passage number of the 
stromal cell cultures affected activity, several cultures 
were initiated and maintained for several months. As 
is depicted in Table IA, levels between 35-45% inhi- 
bition were consistently found in CM from nearly all 
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TABLE I. Inhibition of PC-3 Cell Growth by CM From Different Stromal Cell Cultures* 
~ 
A. Prostate derived stromal cell culturesa B. Nonprostatic stromal cell cultures 
Number of % inhibition Number of % inhibition 
Pass nr CM tested (average) Culture Pass nr CM tested (average) Culture 
PA 517 
PA 518 
PA 519 
PA 520 
PA 526 
PA 527 
PC 239 
PC 242 
PC 245 
PC 259 
.5 
4 
6 
7 
8 
6 
4 
5 
6 
7 
3 
4 
5 
3 
4 
4 
5 
6 
7 
3 
4 
5 
4 
5 
4 
11 
4 
9 
7 
14 
11 
8 
13 
9 
25 
5 
8 
6 
15 
13 
5 
0 
13 
35 
3 
7 
37 
10 
10 
13 
40 
30 
40 
38 
37 
45 
39 
40 
41 
48 
39 
39 
39 
35 
38 
36 
32 
35 
37 
40 
40 
43 
38 
42 
32 
HF 10.3 
Skin 
FS 1 
Foreskin 
Ut 1 
Uterus 
WT 3 
Wilms’ tumor 
WT 7 
Wilms’ tumor 
NN 1 
Kidney 
9 
10 
11 
3 
4 
3 
4 
5 
3 
4 
5 
9 
24 
13 
2 
6 
29 
9 
7 
3 
3 
5 
8 
18 
13 
7 
14 
13 
17 
9 
16 
9 
18 
*Cultures were initiated and subcultured as described in Materials and Methods. Twice a week, CM from confluent monolayers was 
harvested and fresh medium was given. Centrifuged CM was stored at -20°C. Within four weeks, the antiproliferative effect of these 
undialyzed samples was measured. 
“PA, benign prostatic hyperplasia; PC, prostate cancer. 
stromal cell cultures derived from both malignant 
(PC) and nonmalignant (BPH) prostates. However, 
no clear-cut differences in activity were seen between 
CM of subsequent passages. 
Production of Inhibitory Activity by Nonprostatic 
Stromal Cell Cultures 
Table IB lists the growth of PC-3 cells in CM ob- 
tained from stromal cell cultures derived from skin, 
foreskin, normal uterus, Wilms’ tumor, and normal 
kidney tissue. Cultures were initiated, subcultured, 
and CM tested in essentially the same way as pros- 
tate-derived cultures. No biologically significant inhi- 
bition of PC-3 cell growth occurred, especially if it is 
taken into account that 5-10% less growth inhibition 
was observed when depleted nutrients were replaced 
by dialyzing these samples against medium (not 
shown). These data demonstrated that induction of 
inhibitory activity was confined to prostatic stromal 
cells, strongly suggesting an organ-specific produc- 
tion. 
Concentration and Partial Purification of CM 
In order to concentrate inhibitory activity, we per- 
formed an ammonium sulfate precipitation of CM. 
Figure 3 demonstrates that nearly all inhibiting activ- 
ity was found in the pellet formed between 40-50% 
saturation. As a result, the remaining supernatant no 
longer had a negative effect on cell growth. These 
findings indicate that the inhibition was caused by 
precipitable factor(s) in the CM and was not due to 
depletion of nutrients or growth stimulating factors. 
Approximately 25% of the total amount of protein 
originally present in the CM was delivered in the con- 
centrated fraction, while 75% could be discarded. Es- 
sentially the same results were obtained when the 
number of steps was reduced (i.e., 0-40%, 40-50%, 
and 50-100% saturation). Serial dilution curves of 
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Fig. 3. Concentration of inhibitory activity by ammonium sulfate 
precipitation. The saturation level was increased stepwise, and the 
effect of pellet and remaining supernatant tested on PC-3 cell 
growth after dialysis (open dots and left axis). The amount of 
protein in the pellet is given as a percentage of the total protein 
present in the original solution (closed dots and right axis). 
such a preparation are shown in Figure 4. Inhibition 
of PC-3 cell growth reached its maximum of approx- 
imately 60% compared to controls, at a protein con- 
centration of 2 mg/ml. Using other, more concen- 
trated preparations, inhibition levels of up to 90% 
were found at protein concentrations of about 4 mg/ 
ml. In a comparative experiment, bovine serum albu- 
min (BSA) was shown to interfere with cell growth 
only at higher concentrations: approximately 10% in- 
hibition at 6 mg/ml. These findings indicate that the 
observed inhibition of semipurified inhibitor was not 
merely due to a high protein content. Basal medium 
and skin-derived stromal cell CM were fractionated 
by the same procedure in order to investigate the 
possibility that the observed effects were caused by 
concentration and/or activation of serum-derived 
growth inhibitors. The effect of these preparations on 
cell growth (tested at concentrations up to 6 mg/ml) 
did not differ significantly from control cultures, 
again indicating that inhibition caused by prostate 
stromal cell CM was not due to a high protein con- 
centration. 
Inhibition of Epithelial Cell Lines 
As shown in Figure 4A, different human prostatic 
carcinoma (epithelial) cell lines were inhibited when 
grown in monolayer culture. Anchorage-dependent 
growth of both the hormone-insensitive cell line PC-3 
and the androgen-responsive cell line LNCaP was in- 
hibited in a dose-related fashion. Figure 4B illustrates 
Growth [%] 
120 1 
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Pellet 40-50% [~~girnl] 
Fig. 4. Serial dilutions of concentrated CM (Pellet 4040%) on 
(A) human prostatic carcinoma cell lines PC-3 (0) and LNCaP (e), 
and (B) cell lines derived from the Dunning tumor (rat prostate) 
AT2.I (0) and MATLyLu (a). Inoculum: PC-3, 2,000; LNCaP, 
5,000; AT-2. I and MATLyLu, 2,000 cells/well. Bars, SD. 
that similar results were obtained with epithelial cell 
lines AT-2.1 and MATLyLu, derived from the Dun- 
ning rat prostate tumor. These findings indicate that 
the growth-inhibiting factor present in CM did not 
have a species-specific effect. Preliminary tests on pri- 
mary epithelial cell cultures (second passage), de- 
rived from BPH and prostatic carcinoma, showed 
these cells to be inhibited as well. Growth assays per- 
formed on the human breast carcinoma cell line 
MCF-7 as well as on the human renal carcinoma cell 
line RC-21 did not show inhibitory activity (Fig. 5). 
These findings suggest that CM-derived inhibition 
may be prostate-specific. 
DISCUSSION 
Cellular proliferation in the prostate is controlled 
by a complex interaction of different cell types with 
soluble peptide growth factors, (steroid) hormones, 
and constituents of the extracellular matrix. It is likely 
that the array of peptide factors which play a role in 
the regulation of cell attachment and proliferation af- 
fects these processes through both positive and neg- 
ative control mechanisms. Several epithelial cell 
growth-promoting peptides have been identified in 
the prostate and in prostate-derived epithelial cell 
cultures [17,18]; some of them have been positively 
identified as also being produced by stromal cells, 
suggesting a role in stromal-epithelial interactions 
[19-211. Following the observation that urogenital si- 
nus mesenchyme plays a major role in the androgen- 
induced development of the gland [2], stroma has 
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Fig. 5. Serial dilutions of concentrated CM on the breast carci- 
noma cell line MCF-7 and the renal carcinoma cell line RC-21. 
Inoculum: MCF-7, 3,000 RC-2 I, 10,000 cells/well. Bars, SD. 
been recognized as a potential site of disregulation of 
epithelial cell growth, which may eventually lead to 
neoplasia [22]. The fact that prolonged androgen ad- 
ministration to castrated animals does not induce the 
gland to grow beyond its predetermined size [2], to- 
gether with the observation that withdrawal of an- 
drogens decreases epithelial cell number only in the 
in vivo situation where stroma is present [8,5], sug- 
gests a role for stromally-derived epithelial cell 
growth inhibitors in the prostate. 
The results presented in this paper suggest that 
prostatic stromal cells secrete a diffusible epithelial 
cell growth inhibitor(s). Anchored, as well as nonan- 
chored, growth of the hormone-independent pros- 
tatic carcinoma cell line PC-3 and the androgen-re- 
sponsive prostatic carcinoma cell line LNCaP was 
affected. Primary epithelial cell cultures from BPH 
and prostate cancer appeared to be sensitive as well. 
Accumulatnon of antiproliferative activity in the CM 
was positively correlated with cell number and con- 
fined to prostate-derived stromal cells. This organ- 
specific production appears to be a unique property, 
for it has not been described before in prostate re- 
search. Characterization currently underway shows 
that the putative factor appears to be a protein with a 
molecular weight >3.5 Kd, sensitive to reducing 
agents, indicating the presence of S-S bridges that are 
needed for biological activity [23]. Several aspects 
concerning the production are still under investiga- 
tion. For the present, serum-derived factors are re- 
quired for optimal production and/or secretion. We 
failed to demonstrate significant effects of steroids 
(testosterone, dihydrotestosterone, or estradiol) in 
this respect, however. 
That stroma not only induces a mitogenic re- 
sponse, but can also act as a "brake" on the epithe- 
lium, is suggested by observations made on other 
organ systems. Negative regulators of cell growth 
have been demonstrated in other fibroblast cultures 
[24-261. Several coculture experiments as well as in 
vivo studies showed the controlling influence of the 
stroma on the epithelial compartment [27], ranging 
from induction of differentiation [28,29] to tumor cell 
degeneration [30]. Similar experiments carried out on 
the male genital tract fit in with these findings. ROW- 
ley and Tindall [31] found that diffusible factors pro- 
duced by fetal urogenital sinus decreased the prolif- 
eration of bladder carcinoma cells in vitro. Recently, 
Chung et al. [32] showed a marked growth inhibition 
of a hormone-independent rat prostatic tumor cell 
line (Nb-102-pr) when grafted in combination with 
urogenital sinus mesenchyme. Hayashi and Cunha 
[33], performing similar experiments on Dunning 
R3327 rat prostate tumor lines, demonstrated a reduc- 
tion in epithelial cell growth rate and an apparent 
reduction or loss of tumorigenesis of these cells. In- 
deed, those findings indicate that, in the urogenital 
tract, mesenchymal cells are capable of inhibiting ep- 
ithelial cell proliferation. 
Several investigators have studied stromal-epithe- 
lial interactions in the prostate in vitro, but their re- 
ports were mainly focused on the mitogenic influence 
of the stroma [34,35,19,36,21]. Kirk et al. [37] showed 
an inhibition of PC-3 cell growth by lung fibroblasts, 
using a serum-dependent soft agar assay. So far, no 
reports have been published by other groups on stro- 
mally-derived epithelial cell growth inhibitors in the 
(adult) prostate. Remarkably, however, all studies 
demonstrating stromal stimulation of prostatic epi- 
thelial cell growth were performed under serum-free 
conditions. Regarding the lack of a growth stimula- 
tory response of the tumor cell lines to our fibroblast- 
conditioned medium, one might suggest that such an 
effect might have been masked by the relatively high 
serum content (5% FCS) maximally stimulating cell 
proliferation. However, this is contradicted by the 
fact that MTT tests were performed under conditions 
that still allowed stimulation of growth, e.g., in the 
presence of higher serum concentrations. 
During the past decade, much effort has been put 
into the development of systems for serum-free cul- 
ture of prostatic cells. Indeed, a serum-free environ- 
ment is ideal for testing as well as identification of 
regulatory peptides. However, as a consequence of 
this simplification, certain information may be lost, as 
demonstrated by the results presented in this report. 
These considerations bring to light a crucial dilemma 
in oncological research, as stated by D. Smithers: 
"Reduction gains precision about parts but at each 
step loses information about the larger organization it 
leaves behind" [38]. The glandular cells in the pros- 
tate receive nutrients, growth-modulating peptides, 
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trophic nerve factors, and (steroid) hormones that 
have traversed the endothelial cells, stromal cells, ex- 
tracellular matrix, and the acinar basement mem- 
brane. Consequently, the stromal compartment has 
ample opportunity to modify epithelial cell microen- 
vironment. It is conceivable that (perhaps unknown) 
serum-derived factors may very well participate in 
this, for instance, by modifying stromal secretions, as 
was shown for androgen-induced epithelial cell pro- 
liferation in the rat prostate [7]. Thus, tests per- 
formed in the presence of serum or other undefined 
supplements, such as bovine pituitary extract, will 
provide us with useful information about physiolog- 
ical and pathophysiological processes, and are essen- 
tial to basic oncological research. However, these 
supplements will eventually hamper identification 
and isolation of the substance(s) of interest. 
So far, TGFP is the only well-known epithelial cell 
growth inhibitor that has been identified in the pros- 
tate [39,24]. Other inhibitory peptides that have been 
associated with the prostate [40,41,11] are not likely 
candidates for elaborating antiproliferative activity in 
our tests. The presence of TGFP mRNA has been 
demonstrated in human prostatic tissue [13] as well 
as in rat ventral prostate [12]. In vitro studies have 
implicated TGFP as a potent growth inhibitor of pro- 
static epithelial cells, both normal and malignant [42]. 
Kyprianou and Isaacs [12] showed a 40-fold increase 
of TGFp mRNAs four days after castration. Androgen 
administration to four-day castrated rats led to a 
marked decrease in TGFP mRNA, to a level compa- 
rable to its constitutive expression obtained in intact 
control animals, showing that expression of TGFP is 
under negative androgenic regulation. In vitro and in 
vivo experiments showed TGFP to induce pro- 
grammed cell death of rat ventral prostate glandular 
cells (431. Since these studies were performed on 
whole tissue homogenates, no conclusions regarding 
the source of TGFP can be drawn from these tests. 
However, prostatic carcinoma cells have been shown 
to secrete TGFP (391, while the secretion of TGFP by 
fibroblasts from other organs is also well documented 
[24]. The work presented here shows that prostatic 
stroma is also capable of secreting negative mediators 
of epithelial cell growth. Since castration-induced cell 
death mainly takes place in the epithelial compart- 
ment, and the ratio of epithelial to stromal cells 
changes in favor of the stromal part, it is tempting to 
assume that the increase in TGFP mRNA expression, 
an active process, takes place in the less affected cell 
type. Definitive answers, however, can only be ex- 
pected from studies using in situ hybridization tech- 
niques with TGFP-specific probes. 
From this point of view it would be very attractive 
to explain excessive (i.e., neoplastic) growth by a fail- 
ure in this system which may normally regulate pro- 
static size. It could, for instance, be caused by a mu- 
tation in the epithelium, rendering it insensitive to 
these factors [44]. This would also explain why tu- 
mors are able to metastasize without their stroma. 
Recently, elevated levels of TGFP immunoreactivity 
have been associated with prostate cancer 1451. These 
observations may reflect insensitivity of cancer cells, 
possibly associated with a resulting failure in the neg- 
ative feedback loop that controls their production and 
secretion by the stroma. 
In summary, the data presented here demonstrate 
that prostatic stromal cells produce an epithelial cell 
growth-inhibiting activity that may share some prop- 
erties with TGFP. However, especially the results re- 
garding the organ-specific production and action ap- 
pear to distinguish this putative factor from the 
TGFPs, and strengthen the importance of our find- 
ings. It would be very interesting to investigate 
whether this factor is the major "brake" on the pros- 
tate, controlling epithelial proliferation and thus pro- 
static size. Further efforts will be made to unravel the 
identity of this prostatic stroma-derived growth in- 
hibitor. Studies are already in progress about the re- 
lationship of this factor(s) to the type @ Transforming 
Growth Factors mentioned above. 
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